Prevalence of antilipemic drug use in Taiwan: Analysis of a sampling cohort within the National Health Insurance

Journal of the Chinese Medical Association

Volumn 66, Issue 1, 2003, Pages 39-45

  Chen, Tzeng Ji ^a,b   Lin, Shing Jong ^a,b   Chen, Liang Kung ^a,b   Hwang, Shinn Jang ^a,b   Chou, Li Fang ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

Antilipemic agents; Drug utilization; National health programs; Pharmacoepidemiology; Prevalence

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; CLOFIBRATE ALUMINUM; COLESTYRAMINE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; NICERITROL; NICOFURANOSE; NICOMOL; NICOTINIC ACID DERIVATIVE; PRAVASTATIN; PROBUCOL; SIMFIBRATE; SIMVASTATIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CLINICAL RESEARCH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG USE; ESSENTIAL HYPERTENSION; FEMALE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NATIONAL HEALTH INSURANCE; OUTPATIENT DEPARTMENT; PRESCRIPTION; PREVALENCE; SAMPLING; SEX DIFFERENCE; TAIWAN; DRUG UTILIZATION; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PUBLIC HEALTH;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; TAIWAN;

EID: 0038657963     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Martikainen J, Klaukka T, Reunanen A, Peura S, Wahlroos H. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996;49:1453-7.
3. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997;53:185-9.
4. OECD Health Data 2001. Paris: OECD (Organisation for Economic Co-operation and Development), 2001.
5. Su TP, Chen TJ, Hwang SJ, Chou LF, Fan AP, Chen YC. Utilization of psychotropic drugs in Taiwan: I. an overview of outpatient sector in 2000. J Chin Med Assoc 2002;65:378-91.
6. Guidelines for ATC Classification and DDD Assignment, 3rd ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2000.
7. Schappert SM. Ambulatory Care Visits to Physician Offices, Hospital Outpatient Departments, and Emergency Departments: United States, 1997 (Vital Health Statistics, Series 13, No. 143). Hyattsville: National Center for Health Statistics, 1999.
8. Page RM, Cole GE, Timmreck TC. Basic Epidemiological Methods and Biostatistics: A Practical Guidebook. Boston, London: Jones and Bartlett, 1995.
9. Gardner MJ, Altman DG. Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1989.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
11. Pan WH, Chiang BN. Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan - a unique experience. Atherosclerosis 1995;118:285-95.
12. Sketris IS, Kephart GC, Hicks VA, Hubbard EJ, Brown MG, Chandler RF, MacLean DR. Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the Nova Scotia population more than 65 years old. Ann Pharmacother 1995;29:576-81.
13. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000;160:343-7.
14. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women: a reflection of the research evidence? J Clin Epidemiol 2002;55:95-101.
15. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001:87:646-9.
16. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: Does evidence change practice. Arch Intern Med 2001;161:183-8.
17. Harder S, Mohr O, Klepzig H. Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic. Int J Clin Pharmacol Ther 2001;39:534-8.
18. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol 1997;29:139-46.
19. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998;317:1134-5.
20. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999;21:60-4.
21. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
22. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-7.
23. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. BrJ Clin Pharmacol 2000;49:463-71.
24. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther 2000;67:438-41.
25. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001;161:53-8.
26. Lee YT, Lin RS, Sung FC, Yang CY, Chien KL, Chen WJ, et al. Chin-Shan Community Cardiovascular Cohort in Taiwan - baseline data and five-year follow-up morbidity and mortality. J Clin Epidemiol 2000;53:838-46.